Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl
Francesco Forconi(University of Leeds), Francesco Lauria(Ospedale Santa Maria alle Scotte), Ivana Pierri(University of Genoa), Marco Gobbi(Mario Negri Institute for Pharmacological Research), Filíppo Gherlinzoni(Ca' Foncello Hospital), Robin Foà(Sapienza University of Rome), Miriana Ruggeri, Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Gallamini(Centre Antoine Lacassagne), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Giuseppe Polimeno, Francesco Zaja, Emanuele Cencini(University of Siena), Alessandra Caremani(Azienda Usl 8 Arezzo), Benedetta Puccini(Azienda Ospedaliero-Universitaria Careggi), Caterina Stelitano(University of Reggio Calabria), Sara Barulli, Sergio Cortelazzo(Azienda Ospedaliero-Universitaria delle Marche), Renato Cantaffa(Azienda Ospedaliera Pugliese Ciaccio), Piero Galieni, Tamara Intermesoli(University of Bergamo), Alfonso Zaccaria(University of Bologna), Giovanni Martinelli(University of Bologna), Alessandro Levis(San Antonio College), Alessandro Pulsoni(Ospedale Santa Maria Goretti), Elisa Sozzi(University of Siena), Angelo Guerrasio, Luigi Rigacci(Azienda Ospedaliero-Universitaria Careggi), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Luciano Masini(Casa di Cura Villa Garda), Francesca Fiore, Andrea Piccin(Ospedale di Bolzano)
Cited by 8
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k